Ilene Fennoy, MD and Dorit Koren, MD

Mission Statement:

Our mission is to affirm the ideology of the PES as a scientific community that fosters inclusion, acceptance, and support for every person independent of race, ethnicity, gender, sexual orientation, or religion. Towards this end, our focus is to:

  1. Recognize implicit and explicit bias in healthcare in Pediatric Endocrinology, and address related healthcare disparities that affect our patients and families, through research, quality improvement, health delivery science, education, and outreach efforts.
  2. Foster equity and diversity and provide an environment of equality and mentorship for all trainees, fellows, and faculty in Pediatric Endocrinology.


Our task force goals for the coming year are to increase awareness in our society’s membership of implicit and explicit bias in medicine in general and Pediatric Endocrinology specifically, and the contribution of said biases to health care disparities as well as to career development of minority physicians. We also aim to start to amass resources to help us address and ameliorate these biases and resulting disparities. We will contribute regularly to the newsletter, develop a needs assessment survey of our society, and will plan to offer periodic education for the PES membership.


Black History Month is an annual month-long celebration of achievements by Black Americans and a time to celebrate their integral role in Unite States’ history. The story of Black History Month first began in 1915, when historian Carter G. Woodson founded the Association for the Study of Negro Life and History  (ASNLH), one of the first organizations in the United States dedicated to commemorating achievements by Black Americans. Years later, a week-long celebration designated to take place on the second week of February was chosen to coincide with the birthdays of Abraham Lincoln ( February 12)  and Frederick Douglass ( February 14). In 1976, President Gerald Ford officially recognized Black History Month. He encouraged all US citizens to “seize the opportunity to honor the accomplishments of Black Americans throughout our history.” Since 1976, every American president has designated February as Black History Month. Black History Month has also received official recognition in Canada, Ireland and the United Kingdom. We honor the contributions and legacy of Black leaders in all fields of endeavor including civil rights pioneers, leaders in industry, politics, science, and culture. Martin Luther King Jr., Thurgood Marshall, Harriet Tubman, Sojourner TruthMarcus Garvey, Mae Jemison, Rosa Parks, Barbara Jordan, Shirley Chisholm, and Dr. Charles Drew represent only a few of the many individuals who come to mind as individuals whose impact on American Society has been monumental.

This year’s (2023) Black History Month theme, “Black Resistance,” explores how "African Americans have resisted historic and ongoing oppression, in all forms” since the nation's earliest days.


FRIDAY, FEBRUARY 3, 2023 IS NATIONAL WEAR RED DAY in the UNITED STATES, chosen as a day to raise awareness of the importance of a heart-healthy life style. Cardiovascular disease is the leading cause of death in the United States: each year, over 600,000 Americans die of heart disease. Many of these deaths could be prevented through education and adherence to a heart-healthy lifestyle: regular exercise, healthy eating, and avoidance of cigarette smoking. Acquired causes of cardiovascular disease (CVD) including obesity and type II diabetes have become more prevalent in the US and represent a serious public health concern in the pediatric as well as the adult population. Universal lipid screening in children at 9-11 years of age (and again at completion of puberty) and cascade screening and treatment of affected family members will have a dramatic impact in reducing CVD in the population. Statin therapy is the first-line of treatment for youth with familial hypercholesterolemia (FH) and should be started early in adolescence. New therapeutic options for the prevention of cardiovascular disease have emerged over the past few years. Proprotein convertase subtilisin/kexin 9 (PCSK-9) inhibitors (evolocumab,alirocumab), small interfering RNAs ( siRNAs) targeted against PCSK9 mRNA (inclisiran) are well-tolerated and highly effective in lowering  LDL-C levels to therapeutic targets.

February is a good time to focus on heart-healthy lifestyle changes, and to encourage our patients and families to do the same.


Resources for Addressing Implicit Bias:

We encourage you to review these links:

Additional EDI Resources of Interest:

New! EDI Cooking Club - New Date TBD

More info to come!


Email if you are interested in getting involved!